Unlearn’s AI-Powered Clinical Trials with AbbVie and Johnson & Johnson
Unlearn, an AI company, showcased the impact of its technology in two poster sessions at the Alzheimer’s Association International...
New Study: Alzheimer’s Progression Explored with Revolutionary Cell Platform
Groundbreaking research has led to a novel model using human induced pluripotent stem cell (iPSC)-derived cortical neurons to understand...
Evolus Obtains Approval For Botox in Australia
Evolus, a performance beauty company focused on aesthetics, has launched operations in Australia by introducing Nuceiva (prabotulinumtoxinA). This marks...
BioAge Announces Groundbreaking Obesity Treatment Trial
BioAge Labs has initiated a Phase 2 clinical trial, STRIDES, to assess the efficacy of azelaprag, a small molecule...
Venetoclax and Fixed-Duration Calquence® Significantly Improve Leukemia Survival
An interim analysis of the AMPLIFY Phase III trial has revealed encouraging results in the treatment of chronic lymphocytic...
Seqster’s Digital Health Technology: Unveiling a Revolutionary Alzheimer’s Screening Breakthrough
SEQSTER PDM Inc. and Boston University researchers, led by Dr. Rhoda Au, have partnered to develop an innovative early...
FDA on The Exciting Future of Clinical Trial Regulatory Affairs
The 2024 DIA conference hosted a session, Regulatory Affairs of the Future is Now, which was a dynamic and...
Aditxt Inks Agreement with Appili, Aiming for September Acquisition
Appili Therapeutics, a biopharmaceutical company specializing in infectious disease treatments and vaccines, has secured CAD $100 million in funding...
Viridian Therapeutics Announces: Thrive-2 Enrollment Complete for Ted Patients
Viridian Therapeutics announced the completion of enrollment in its phase 3 clinical trials, THRIVE and THRIVE-2, targeting patients with...
FDA Approves Mirum’s Livmarli for PFIC in 12-Month-Olds and Up
Mirum Pharmaceuticals has received FDA approval to expand the use of LIVMARLI (maralixibat) oral solution for treating cholestatic pruritus...